It depends on the standard you follow. As of September 2026, Mirum Pharmaceuticals, Inc. (MIRM) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 12.6% / 30% · (Cash+Inv) / Mkt Cap (36m) 8.62% / 30% · Interest income / Revenue 2.52% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 12.6% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 6.44% / 33% · Receivables / Mkt Cap (36m) 2.69% / 49% · Interest income / Revenue 2.52% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 12.6% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 6.44% / 33.33% · Receivables / Mkt Cap (24m) 2.69% / 33.33% · Interest income / Revenue 2.52% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 55.2% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 41.6% / 33.33% · Receivables / Avg Assets (4Q) 14.7% / 33.33% · Interest income / Revenue 2.52% / 5% | Fail |
| FTSE | Debt / Total Assets 71.2% / 33.33% · (Cash+ST Inv) / Total Assets 36.4% / 33.33% · (Cash+Recv) / Total Assets 51.6% / 33.33% · Interest income / Revenue 2.52% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Mirum Pharmaceuticals, Inc. (MIRM) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Mirum Pharmaceuticals, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 2.52% of each dividend: Mirum Pharmaceuticals, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) is a Healthcare company (Biotechnology) with a market capitalization of $6.0B. The Maz Rating grades it against the other companies in its sector.
Mirum Pharmaceuticals, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $91.95, Mirum Pharmaceuticals, Inc. trades at 8.9x sales. Over the last twelve months it generated about $676M of revenue and a net loss of $1.0B. It runs a gross margin of 81.7%, an operating margin of -25.3% and a net margin of -134.8%. It shows return on equity of -734.0%, return on invested capital of -22.8% and a free cash flow yield of -8.4%. On the balance sheet: a debt-to-equity ratio of -13.72 and a current ratio of 2.07. Over the past 52 weeks the share price ranged from $63.23 to $130.00, with a beta of 0.49.
Mirum Pharmaceuticals, Inc. does not currently pay a dividend.
18 Wall Street analyst ratings cover the stock: 1 Strong Buy and 17 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.